



# Alzheimer's Disease


## Related Compounds




Huperizine A




Desoxypeganine HCl




Enalapril



Galanthamine Hydrobromide



Citalopram Hydrobromide



Estradiol

Desoxypeganine hydrochloride is an Acetylcholinesterase inhibitor. It is used in the treatment of Alzheimer's dementia<sup>1</sup>. Enalapril is an antihypertensive agent known to reduce the incidence of vascular dementia and Alzheimer's disease. Found to have a potential for colon cancer prevention. (ACE inhibitor)<sup>2</sup>. Estradiol is a potent mammalian estrogenic hormone, useful in the prevention of neuro degenerative diseases, such as Alzheimer's and Parkinson disease, in both men and women. Found to be major steroid mitogen in premenopausal women<sup>3</sup>. Galanthamine HBr is a cholinesterase inhibitor used in the treatment of Alzheimer's disease. It potentiates nicotine-evoked increases in intracellular Ca<sup>2+</sup> and [3H] noradrenaline release<sup>4</sup>. Citalopram HBr is a selective serotonin reuptake inhibitor and antidepressant. It has shown evidence of being effective at reducing aberrant motor behaviors in Alzheimer's disease<sup>5</sup>. Natural product from *Lycopodium serratum* Thunb. It is a potent acetylcholinesterase inhibitor with neuroprotective properties that are of interest in the treatment of Alzheimer's disease. It has been shown to inhibit staurosporine-induced apoptosis<sup>6</sup>. LKT Laboratories also offers Galanin, Rat; Galanin, porcine; and Galanin, human peptides. Galanin is a neuropeptide found to be associated with Alzheimer's disease<sup>7</sup>.

1. Tuliaganov N, Sadritdinov FS, Suleimanova GA. *Farmakol Toksikol*.49:37-40(1986).Lockhart B, Closier M, Howard K, Steward C, Lestage P. *Naunyn Schmiedeberg Arch Pharmacol*. 363:429-38(2001).

2. Frishman WH. *Heart Dis*.4:380-6(2002).Yasumaru M et al. *Cancer Res*.63:6726-34(2003).

3. Bhavnani BR. *J Steroid Biochem Mol Biol*. 85:473-82(2003).

4. Sweeney JE, Puttfarcken PS, Coyle JT. *Pharmacol Biochem Behav*. 34:129-37 (1989).Lilienfeld S. *CNS Drug Rev*. 8:159-76 (2002).

Dajas-Bailador FA, Heimala K, Wonnacott S. *Mol Pharmacol*. 64:1217-26 (2003).

5. "Scharre DW, Davis RA, Warner JL et al. *Am J Geriatr Psychiat*. 11:687-91 (2003).Pousti A, Deemyad T, Malihi G. *Hum Psychopharm*. 19:347-50 (2004).

6. Zhang HY, Tang XC. *Neurosci Lett*. 340:91-4 (2003).Wang LS, Zhou J, Shao XM et al. *Zhonghua Er Ke Za Zhi*. 41:42-5 (2003). Zhang HY, Yan H, Tang XC. *Neurosci Lett*. 360:21-4 (2004).

7. Counts SE, Perez SE, Ginsber SD et al. *Mol Interv*. 3:137-56 (2003).

